Influence of the Maternal Use of Labetalol on the Neurogenic Mechanism for Cerebral Autoregulation Assessed by Means of NIRS
Labetalol is a drug used in the treatment of hypertensive disorders of pregnancy (HDP). In a previous study we investigated the influence of the maternal use of labetalol on the cerebral autoregulation (CA) mechanism of neonates. In that study, we found that labetalol induces impaired CA during the first day of life, with CA returning to a normal status by the third day after birth. This effect was hypothesized to be caused by labetalol-induced vasodilation. However, no strong evidence for this claim was found. In this study we aim to find stronger evidence for the vasodilation effect caused by labetalol, by investigating its effect on the neurogenic mechanism (NM) involved in CA. The status of the NM was assessed by means of transfer function analysis between the low frequency content of the autonomic control activity (LFA), obtained by processing of the heart rate (HR), and the regional cerebral oxygen saturation (rScO2). We found that neonates from mothers treated with labetalol presented a lower LFA and an impaired NM response during the first day of life, with values returning to normal by the end of the third day. These results reflect a vasodilation effect caused by labetalol, and indicate that the impaired CA observed in the previous study is caused by vasodilation.
KeywordsLabetalol Hypertensive disorders of pregnancy Vasodilation effect Neurogenic mechanism Cerebral autoregulation
Research supported by a postdoctoral mandate of the KU Leuven (BOF-KU Leuven) and: Research Council KUL: GOA MaNet, PFV/10/002 (OPTEC), IDO 08/013 Autism, several PhD/postdoc & fellow grants. Flemish Government: FWO: PhD/postdoc grants, projects: G.0427.10N (Integrated EEG-fMRI), G.0108.11 (Compressed Sensing) G.0869.12N (Tumor imaging) G.0A5513N (Deep brain stimulation); IWT: TBM070713-Accelero, TBM080658-MRI (EEG-fMRI), TBM110697-NeoGuard, PhD Grants; iMinds 2013; Flanders Care: Demonstratieproject Tele-Rehab III (2012–2014). Belgian Federal Science Policy Office: IUAP P719/(DYSCO, `Dynamical systems, control and optimization', 2012–2017); ESA AO-PGPF-01, PRODEX (CardioControl) C4000103224. EU: RECAP 209G within INTERREG IVB NWE programme, EU HIP Trial FP7-HEALTH/ 2007–2013 (n° 260777), EU MC ITN Transact 2012 # 316679 y carito linda.
- 5.Caicedo A and Van Huffel S (2010) Weighted LS-SVM for function estimation applied to artifact removal in biosignal processing. Proceedings of the 32nd annual international conference of the IEEE Engineering in Medicine and Biology Society (EMBC 2010), Buenos Aires, Argentina, August 31–September 4, pp 988–991Google Scholar